eltrombopag
Selected indexed studies
- Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. (N Engl J Med, 2017) [PMID:28423296]
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. (Lancet, 2011) [PMID:20739054]
- Eltrombopag. (Cancer Treat Res, 2011) [PMID:21052963]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. (2017) pubmed
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. (2011) pubmed
- Eltrombopag. (2011) pubmed
- Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). (2023) pubmed
- Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis. (2021) pubmed
- Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. (2017) pubmed
- Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. (2022) pubmed
- Eltrombopag in aplastic anemia. (2015) pubmed
- Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis. (2025) pubmed
- Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. (2024) pubmed